- | X4 Pharmaceuticals
Dr. Ragan Discusses X4’s Work To Advance Disease-Modifying For Rare Genetic Diseases | Podcast
Dr. Ragan discusses X4 Pharmaceuticals, which is currently developing therapies for rare genetic diseases that result from dysfunction of the immune system and is currently undergoing a global Phase 3 trial for WHIM Syndrome and two Phase 1b trials for Waldenstrom macroglobulinemia (WM), a type of rare lymphoma, and severe congenital neutropenia (SCN).
- | Vaxart
Developing Effective COVID-19 Oral Vaccine in Tablet Form with Sean Tucker Vaxart
Sean Tucker, Founder and Chief Scientific Officer, Vaxart is on a mission to expand the choices for a COVID-19 vaccine by producing an effective oral vaccine in tablet form which would allow for more efficient distribution and ease of administering particularly to needle-adverse people. Building on experience developing an oral tablet for an influenza vaccine, Vaxart has created a technology to trick the immune system in the intestine to recognize the protein as something that needed to mount immune response and then develop memory so that it works as a vaccine.
- | Amolyt Pharma
Peptidream, Amolyt alliance focuses on potential acromegaly treatment
Peptidream Inc. inked a research collaboration with Amolyt Pharma SAS to test and optimize Peptidream’s growth hormone receptor antagonist (GHRA) peptides, with the aim of selecting a candidate to develop as a potential treatment for acromegaly.
- | X4 Pharmaceuticals
X4 Pharma Adjusts Clinical Trials For A COVID World
X4 Pharma is a company focused on delivering innovative treatments for patients with rare diseases of the immune system. With the COVID pandemic afflicting patients around the world, those with a compromised immune system were at even greater risk.
- | Leading Biosciences
Seneca Biopharma merges with Leading BioSciences, becoming Palisade Bio
Penny stock biotech Seneca Biopharma has found a lifeline in privately owned Leading BioSciences as it merges with the biotech.
- | INmune Bio
Dr. CJ Barnum of INmune Bio | NIH Grant tests Neuroinflammation on Treatment Resistent Depression
We sit down with Dr. CJ Barnum, Director of Neuroscience at INmune Bio, Inc. to talk about the recently announced grant from the NIH for $2.9 million to test a new hypothesis that #neuroinflammation plays a major role in treatment resistant depression (TRD).
- | Sio Gene Therapies
Sio Gene Therapies posts positive PhI/II data in rare pediatric disease, the first readout since its name change
A little over a month after a full company rebrand, the Biotech Formerly Known as Axovant has its first data readout under its new moniker.
